X-Square Capital’s Nuvation Bio NUVB Stock Holding History

X-Square Capital’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-310,000	Closed	-$605K	–	167
2025 Q2	$605K	Buy	+310,000	New	+$646K	0.22%	106

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

X-Square Capital's NUVB Position: Q3 2025 in Review

X-Square Capital sold out of Nuvation Bio (NUVB) in Q3 2025, closing a stake of 310,000 shares — an estimated $605K sold.

X-Square Capital first reported a position in NUVB in Q2 2025 and held it in 1 quarter. The position peaked at $605K in Q2 2025. 203 funds tracked by Wall St. Rank hold NUVB as of Q3 2025.

X-Square Capital reported no remaining Nuvation Bio position as of Q3 2025 after selling out during the quarter.
X-Square Capital sold 310,000 Nuvation Bio shares in Q3 2025, an estimated $605K.
X-Square Capital first reported a position in Nuvation Bio in Q2 2025 and held it in 1 quarter.
X-Square Capital's Nuvation Bio position peaked at $605K in Q2 2025.
203 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2025.

Based on X-Square Capital's 13F filing for Q3 2025, filed 10 Nov 2025.